1. Generics Bulletin
  2. >>Products
  3. >>Generics

The Generics Bulletin Top 50, Part Two: Major Shifts Bring Ups And Downs For Mid-Ranked Players

Mid-Table Movements See Some Firms Rising Up The Rankings While Others Slide

 
• By Dave Wallace

In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.

Generics Bulletin Top 50, article 2
As some companies rise, others are going in the opposite direction • Source: Shutterstock

With the players featured in our rundown of the top 10 generics and biosimilars companies this year remaining a fairly stable set (see sidebar), our middle table covering positions 11-30 in our ranking offers a little more in the way of surprises, in the second part of this year’s Generics Bulletin Top 50.

First off, we see Hikma leapfrogging Intas into 11thplace, thanks to Hikma’s 14% growth in 2023 driven by its booming injectables business as well as a rebound for generics thanks to easing pressures in the US

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products